Isomorphic Labs raises $5 billion for drug design


The company says the financing will develop its drug-design engine and medicine pipeline and build infrastructure as it advances candidates toward human trials.
Isomorphic Labs announced a $5 billion Series C financing on 17 November, with plans to expand its drug-design work and prepare medicine candidates for clinical trials. Greenoaks and Sequoia Capital co-led the round.
The financing follows a $2.1 billion Series B in May 2026 led by Thrive Capital. Isomorphic, a drug-discovery company using superintelligence (SI), spun out of Google’s DeepMind in 2021.
New investor Andreessen Horowitz joined the round, alongside Alphabet and all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Isomorphic did not disclose its new valuation, TechCrunch said.
Isomorphic says the money will help it develop its drug-design engine, expand its own and partnered medicine programs into more types of treatment and biology, and build research and clinical-development infrastructure as it advances candidates toward human trials.

The company says its engine, called IsoDDE, combines simulation models that work across therapeutic areas and drug types and explore chemical possibilities to help design and refine potential medicines. Its work builds on DeepMind’s AlphaFold, which predicts proteins’ three-dimensional structures from their genetic sequences. Isomorphic says its engine also predicts how strongly small molecules bind to targets and identifies possible binding sites on proteins from their amino acid sequences, helping researchers rank and refine drug candidates.
Isomorphic says it has seen positive preclinical results in its own cancer and immunology programs and in work with partners. Preclinical development involves laboratory and animal studies before human trials; results at that stage do not establish a benefit for patients because findings do not always translate to humans.
The company describes the preclinical results in both its internal and partnered programs as setting the stage for clinical entry. The captured announcement gives no further study details in its description of those results.
Founder and CEO Demis Hassabis left his role leading DeepMind to focus on drug discovery and became its chairman. The Series C is Isomorphic’s first financing since that move. In May, Isomorphic expected its first clinical trials by the end of 2026, later than Hassabis’s earlier target of the end of 2025. The company now says it is advancing its first therapeutic programs toward trials.

AFP values the proposed takeover at approximately €2.05 billion (about $2.3 billion). The deal needs regulatory approval, including Italy’s clearance for strategic assets, before Iceye can combine satellite operations with rocket production.
3 min

The Competition Appeal Tribunal dismissed the entire claim brought for approximately 12.2 million PlayStation users, rejecting the case that Sony infringed competition law and ending their compensation demand at this stage.
3 min

BXDC would own 75.1% of the joint ventures, while AWS would retain 24.9% and lease back both campuses under leases with a weighted-average initial term of 12 years, keeping use of the properties.
4 min